Previous 10 | Next 10 |
Arcus Biosciences (RCUS) posts positive preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, in metastatic pancreatic cancer at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI).The ongoing, open-lab...
- 41% objective response rate (ORR) observed to-date across first four cohorts in the Phase 1 dose-escalation portion of ARC-8, comparing favorably to the current standard-of-care - Initiated Phase 1b expansion portion of study Arcus Biosciences, Inc. (NYSE:RCUS), an...
- Preliminary data from the first dose-escalation cohorts, reported in an abstract released today, demonstrate encouraging signs of clinical activity for AB680 in combination with zimberelimab (anti-PD-1 antibody) and chemotherapy - Additional data, as of a cut-off date of Dec...
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlman, M.D., Ph.D. and Michael Quigley, Ph.D. have joined the Company’s Board of Directors. Dr. Perlman will also ser...
Arcus Biosciences ([[RCUS]] +2.6%) has expanded its existing strategic relationship with WuXi Biologics ([[WXXWY]] -65.6%) to discover anti-CD39 antibodies using the latter’s proprietary technology. It is the fourth antibody development program for which the two firms have collabo...
- Agreement expands upon Arcus’s industry-leading portfolio of clinical-stage molecules in the adenosine axis - Arcus to be granted exclusive worldwide rights Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create ...
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the Evercore ISI 3 rd Annual HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 10:30 a.m...
Surface Oncology (SURF) has announced that both of its lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), have achieved predefined criteria for advancement into combination and expansion stages of ongoing Phase 1 trials.Phase 1/1b trial of SRF617 was initiated in March for s...
Arcus Biosciences (RCUS): Q3 GAAP EPS of $0.03 beats by $0.62.Revenue of $64.53M (+3587.4% Y/Y) beats by $59.39M.Press Release For further details see: Arcus Biosciences EPS beats by $0.62, beats on revenue
- Commenced 10-year highly strategic partnership with Gilead to deliver next-generation cancer therapies - Recently announced collaboration with AstraZeneca for registrational trial, PACIFIC-8, further validates domvanalimab’s therapeutic potential - Significant...
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8 th , 2024 at 2 PM...
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...